PEATY
Research type
Research Study
Full title
Perceptions and experiences of abemaciclib and endocrine therapy
IRAS ID
298216
Contact name
Lesley Fallowfield
Contact email
Sponsor organisation
University of Sussex
Duration of Study in the UK
0 years, 11 months, 30 days
Research summary
This study is looking at the expectations and experiences of women who are receiving abemaciclib (a targeted cancer drug) and hormone (or endocrine) therapy for early breast cancer that is at high risk of recurrence. This treatment is fairly new and little is known about what patients expect, their experiences during treatment and how they manage any possible side-effects. We know for example that diarrhoea (sometimes severe) is a common side effect of abemaciclib and usually starts during the first weeks of treatment. Finding out how people experience treatment, how well they deal with any problems and understanding their needs, is essential to aid the development of helpful information materials that will best inform and support them.
In this study, we will invite 25-30 women from the POETIC-A trial to take part in a series of three interviews. The first interview is before or shortly after starting study treatment to find out what their treatment expectations are and what they know about the drugs they have been prescribed. The follow-up interviews will take place 4 and 8 weeks later to find out if their treatment experiences met their expectations. We would like to know especially if they had diarrhoea, what steps they may have taken to reduce it, and how successful this was.
We hope that the results of the study can be used to develop materials to help doctors communicate better the side-effects of treatment, and more importantly how effective different ways to deal with these might be. Our work has real potential to benefit patients by changing the way we support people who are receiving abemaciclib, and help them to fulfil their everyday life roles and responsibilities.
REC name
London - Chelsea Research Ethics Committee
REC reference
21/PR/0853
Date of REC Opinion
29 Jul 2021
REC opinion
Further Information Favourable Opinion